卖什么
Growing micro-organs to find new drugs
商业模式拆解
买家：谁掌握预算？
未核实Pharma/biotech partners and funders (site has a Partnership section); rare-disease families supply patient mutations. Analyst inference.
工作流：什么输入变成什么输出？
Model human development with organoids carrying the same gene mutation as the child, then screen drugs in those models to find therapies for rare genetic diseases.
经济账：省了什么，怎么收费？
Early-stage therapy developer; no revenue model stated. Site cites that only 5% of rare diseases have approved treatments.
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| — | YC 2022 冬季 | — | Y Combinator | ycombinator.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.